News Release

Information
Q&A of Cullgen and Astellas’ Collaboration Agreement
Information
Notice of maintenance and upgrade of our website
Information
GNI Group summary Q&A from Q1 2023 financial results analyst call and other recent inquiries
Information
GNI Group FY2023Q1 Earnings Call Transcript
Information
CBIO files 2023Q1 10-Q (quarterly report)
Information
CBIO submits Form 8-K regarding its Nasdaq listing status
Information
GNI Group summary Q&A from FY2022 AGM
Information
CBIO filed 10-K
Information
22nd Annual General Meeting of Shareholders Measures to Prevent the Spread of Covid 19
Information
Impacts of Silicon Valley Bank closure
Information
GNI Group summary Q&A from full-year 2022 financial results analyst call and other recent inquiries
Information
Resuming normal office operations
Information
2023 New Year Greeting
Information
FAQ for Our Disclosure on December 27, 2022, “GNI Group and Catalyst Biosciences Signed Agreements to Advance Liver Fibrosis Drug Development”